Abstract
The somatostatin analogue pasireotide is a new type of protein which is the first therapeutic agent targeted to the pituitary.Pasireotide can prevent adrenocorticotropic hormone release and inhibit the growth of tumor cells after coupling with somatostatin receptor of the target cell membranes.Pasireotide has a high binding affinity for most of somatostatin receptor (SSTR) subtypes and in particular for SSTR5.Pasireotide can paly an important role in the new round of new targets for individualized diagnosis and treatment of tumors through the studies of translational medicine. Key words: Receptors,somatostatin ; Nuclear medicine ; Translational medicine ; Pasireotide ;
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
